0001225208-17-002445.txt : 20170206 0001225208-17-002445.hdr.sgml : 20170206 20170206153514 ACCESSION NUMBER: 0001225208-17-002445 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170203 FILED AS OF DATE: 20170206 DATE AS OF CHANGE: 20170206 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Holston Michael J CENTRAL INDEX KEY: 0001390613 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 17575481 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 4 1 doc4.xml X0306 4 2017-02-03 0000310158 Merck & Co., Inc. MRK 0001390613 Holston Michael J MERCK & CO., INC. 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 1 EVP, General Counsel Common Stock 2017-02-03 4 M 0 41279.0000 59.8600 A 105559.2270 D Common Stock 2017-02-03 4 M 0 36680.0000 58.2200 A 142239.2270 D Common Stock 2017-02-03 4 S 0 14000.0000 63.6904 D 128239.2270 D Common Stock 2017-02-03 4 S 0 77959.0000 64.0027 D 50280.2270 D Stock Option (right to buy) 59.8600 2017-02-03 4 M 0 41279.0000 0.0000 D 2016-05-01 2025-04-30 Common Stock 41279.0000 82560.0000 D Stock Option (right to buy) 58.2200 2017-02-03 4 M 0 36680.0000 0.0000 D 2015-05-09 2024-05-08 Common Stock 36680.0000 18341.0000 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.5100 to $63.8900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.0000 to $64.0300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Holdings include shares acquired in dividend reinvestment transactions. The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. The option became exercisable in equal installments on 5/9/2015, 5/9/2016 and 5/9/2017. Katie Fedosz as Attorney-in-Fact for Michael J. Holston 2017-02-06